Jynneos Now Commercially Available for Vaccination Against Mpox

Bavarian Nordic has announced the commercial availability of Jynneos^® (smallpox and monkeypox vaccine, live, nonreplicating) for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox and mpox infection.

Originally approved in 2019, Jynneos was developed in collaboration with the US government to ensure a supply of a smallpox vaccine for the entire population. During the mpox outbreak in 2022, the US Department of Health and Human Services expanded access to the vaccine to mitigate the spread of the infection. The commercial launch of Jynneos allows health care providers to order the vaccine and make it available to patients in physician offices and pharmacies, in addition to public health clinics. 

In October 2023, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of routine use of Jynneos for the prevention of mpox disease in adults with certain risk factors. Previously, the ACIP had recommended the vaccine for use only during an outbreak. The recommendation was adopted by the Director of the CDC and is now included in the 2024 adult immunization schedule. Additionally, under the Food and Drug Administration’s emergency use authorization, Jynneos may be administered to individuals less than 18 years of age who are determined to be at high risk for mpox infection.

“From the beginning of the mpox outbreak, almost 2 years ago, the prompt availability of an approved vaccine combined with a strong public health response have helped to significantly reduce the impact of this debilitating disease, but unfortunately, mpox has not gone away completely,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. “We look forward to working with health care providers across the nation to increase awareness and availability of the mpox vaccine.”

Jynneos is administered by subcutaneous injection as 2 doses (0.5mL each) 4 weeks apart. Each vial contains a single dose (0.5mL).